Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) PT Raised to $24 at H.C. Wainwright
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) call put ratio 9.7 calls to 1 puts with a focus on January 8 and 9 calls
-
-
-
-
-
-
-
Vanda gets FDA extension for tradipitant motion sickness drug review
-
-
-
-
-
-
-
Vanda Pharmaceuticals receives FDA orphan drug status for polycythemia vera drug
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Announces Bysanti NDA Filing; FDA Decision Expected in Early 2026
-
447,325 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

